Dr Mark Linch is an Associate Professor at University College London (UCL) Cancer Institute, where he leads the Urological Cancer Biology Group, and Honorary Consultant Medical Oncologist.
Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now known as the Francis Crick Institute. He continued his post-doctoral studies at the LRI while also working as a Consultant Medical Oncologist at RMH.
In 2014 Dr Linch moved to UCL to specialise in the clinical management and translational biology of prostate and bladder cancer. His research is focused on the immune biology of these cancers with a view to identifying rational immunotherapy combinations, predictive biomarkers and novel liquid biopsy strategies. He is chief investigator of a number national and international combination immunotherapy trials in bladder and prostate cancer (DURANCE, NEPTUNES, Pro-MERIT), is Chair of the UK Prostate Cancer 100,000 genome project group and is an inaugural member of the UK Bladder Cancer Translational Group. He is funded by the NIHR/BRC, CRUK, Rosetrees Trust, Prostate Cancer Foundation, Prostate Cancer UK and Sir Peter Wood.
